Management Options for Refractory Chronic Myeloid Leukemia: Considerations for the ElderlyBRECCIA, Massimo; ALIMENA, Giuliana.Drugs & aging. 2013, Vol 30, Num 7, pp 467-477, issn 1170-229X, 11 p.Article

The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib eraBRECCIA, Massimo; ALIMENA, Giuliana.Critical reviews in oncology/hematology. 2011, Vol 79, Num 2, pp 135-143, issn 1040-8428, 9 p.Article

Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacyBRECCIA, Massimo; MOLICA, Matteo; ZACHEO, Irene et al.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 11, pp 1621-1630, issn 1465-6566, 10 p.Article

Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety dataBRECCIA, Massimo; TIRIBELLI, Mario; ALIMENA, Giuliana et al.Critical reviews in oncology/hematology. 2012, Vol 84, Num 1, pp 93-100, issn 1040-8428, 8 p.Article

Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemiaBRECCIA, Massimo; SERRAO, Alessandra; SALAROLI, Adriano et al.British journal of haematology. 2012, Vol 159, Num 5, pp 612-613, issn 0007-1048, 2 p.Article

Ten-year follow-up of a single center prospective trial of unmanipulated peripheral blood stem cell autograft and interferon-α in early phase chronic myeloyd leukemiaMELONI, Giovanna; CAPRIA, Saveria; VIGNETTI, Marco et al.Haematologica (Roma). 2001, Vol 86, Num 6, pp 596-601, issn 0390-6078Article

Granulocytic sarcoma of the pancreas successfully treated with intensive chemotherapy and stem cell transplantationBRECCIA, Massimo; D'ANDREA, Mariella; MENGARELLI, Andrea et al.European journal of haematology. 2003, Vol 70, Num 3, pp 190-192, issn 0902-4441, 3 p.Article

Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimenBRECCIA, Massimo; PETTI, Maria Concetta; D'ELIA, Gianna Maria et al.European journal of haematology. 2002, Vol 68, Num 1, pp 1-3, issn 0902-4441Article

Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitorsBRECCIA, Massimo; STAGNO, Fabio; MONTEFUSCO, Enrico et al.American journal of hematology. 2011, Vol 86, Num 6, pp 523-525, issn 0361-8609, 3 p.Article

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)AMADORI, Sergio; SUCIU, Stefan; TORELLI, Giuseppe et al.British journal of haematology. 2010, Vol 149, Num 3, pp 376-382, issn 0007-1048, 7 p.Article

Sudden blast crisis in patients with philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapyALIMENA, Giuliana; BRECCIA, Massimo; LATAGLIATA, Roberto et al.Cancer. 2006, Vol 107, Num 5, pp 1008-1013, issn 0008-543X, 6 p.Article

Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic respondersBONIFAZI, Francesca; DE VIVO, Antonio; KLUIN-NELEMANS, Hanneke C et al.Blood. 2001, Vol 98, Num 10, pp 3074-3081, issn 0006-4971Article

Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistanceBRECCIA, Massimo; BOCCHIA, Monica; CANNELLA, Laura et al.British journal of haematology. 2010, Vol 150, Num 2, pp 240-242, issn 0007-1048, 3 p.Article

Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib : need of quantitative molecular procedures to modulate imatinib doseBRECCIA, Massimo; CILLONI, Daniela; CANNELLA, Laura et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 6, pp 1161-1163, issn 0344-5704, 3 p.Article

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet StudyBACCARANI, Michele; ROSTI, Gianantonio; LEVATO, Luciano et al.Blood. 2009, Vol 113, Num 19, pp 4497-4504, issn 0006-4971, 8 p.Article

Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular ResponsePALANDRI, Francesca; LACOBUCCI, Ilaria; VARALDO, Riccardo et al.Clinical cancer research (Print). 2009, Vol 15, Num 3, pp 1059-1063, issn 1078-0432, 5 p.Article

Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early interventionBRECCIA, Massimo; ORLANDI, Sonia M; ALIMENA, Giuliana et al.British journal of haematology. 2011, Vol 152, Num 1, pp 119-121, issn 0007-1048, 3 p.Article

Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemiaLATAGLIATA, Roberto; BRECCIA, Massimo; AMADORI, Sergio et al.British journal of haematology. 2008, Vol 143, Num 5, pp 681-689, issn 0007-1048, 9 p.Article

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg : outcome of the patients alive after a 6.year follow-upPALANDRI, Francesca; CASTAGNETTI, Fausto; VARALDO, Riccardo et al.Haematologica (Roma). 2008, Vol 93, Num 12, pp 1792-1796, issn 0390-6078, 5 p.Article

Cost analysis of a domiciliary program of supportive and palliative care for patients with hematologic malignanciesCARTONI, Claudio; BRUNETTI, Gregorio Antonio; D'ELIA, Gianna Maria et al.Haematologica (Roma). 2007, Vol 92, Num 5, pp 666-673, issn 0390-6078, 8 p.Article

Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase : results of a phase II study of the GIMEMA CML Working PartyROSTI, Gianantonio; IACOBUCCI, Ilaria; IULIANO, Franco et al.Haematologica (Roma). 2007, Vol 92, Num 1, pp 101-105, issn 0390-6078, 5 p.Article

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceKANTARJIAN, Hagop M; GILES, Francis; BHATIA, Ravi et al.Blood. 2007, Vol 110, Num 10, pp 3540-3546, issn 0006-4971, 7 p.Article

Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective StudyLATAGLIATA, Roberto; FERRERO, Dario; TIRIBELLI, Mario et al.Drugs & aging. 2013, Vol 30, Num 8, pp 629-637, issn 1170-229X, 9 p.Article

Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experienceGIRMENIA, Corrado; MARIA FRUSTACI, Anna; BRECCIA, Massimo et al.Haematologica (Roma). 2012, Vol 97, Num 4, pp 560-567, issn 0390-6078, 8 p.Article

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working PartyGUGLIOTTA, Gabriele; CASTAGNETTI, Fausto; GHERLINZONI, Filippo et al.Blood. 2011, Vol 117, Num 21, pp 5591-5599, issn 0006-4971, 9 p.Article